Hatchtech board and management changes
biotechnology company Hatchtech Pty Ltd announced that Paul MacLeman has resigned as Chief Executive Officer and Director. The company congratulates Dr MacLeman who is leaving to take up the CEO role at a high profile publicly listed biotechnology company.
Since joining Hatchtech in 2005, Dr MacLeman and the board, management and advisors, have moved the company from research to Phase II human trials of the single treatment head lice control product DeOvo™. This is a new generation low-toxicity lousicide that is expected to be the first highly effective treatment for human head lice.
Dr MacLeman will continue with Hatchtech until the end of April.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Cunningham_Drug_Stores_Ltd.
Diisopropylfluorophosphate
On_the_Origin_of_the_‘Influencing_Machine’_in_Schizophrenia

A light switch inside the brain - Scientists from Freiburg Build a Microimplant that Uses a Laser to Control Individual Nerve Cells
Sylvia_Frumkin

Closing the gate to mitochondria
James_B._Sumner
Cyclacel
